Aytu Biopharma (AYTU) Asset Writedowns and Impairment (2020 - 2026)

Aytu Biopharma (AYTU) has reported Asset Writedowns and Impairment for 7 consecutive years, with $700000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 600.0% year-over-year to $700000.0 in Q1 2026; TTM through Mar 2026 was $9.9 million, a 617.31% increase from a year earlier, with the FY2025 full-year figure at $8.3 million, up 588.58% from the prior year.
• Asset Writedowns and Impairment was $700000.0 for Q1 2026 at Aytu Biopharma, down from $800000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $45.2 million in Q1 2022 and troughed at $100000.0 in Q3 2022.
• A 5-year average of $4.3 million and a median of $300000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment surged 2500.0% in 2022 and slumped 99.78% in 2023, its largest moves.
• Over 5 years, Asset Writedowns and Impairment stood at $2.6 million in 2022, then sank by 96.15% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then surged by 700.0% to $800000.0 in 2025, then declined by 12.5% to $700000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $700000.0 (Q1 2026), $800000.0 (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.